Why Commercial Logic Fails in VHA and DHA

Bottom Line:

Manufacturers stall their federal growth by treating specialized government health care system the same as standard commercial accounts, effectively ensuring their clinical value remains misaligned with the fundamental mission of the agencies.

In commercial markets, manufacturers compete through pricing strategies, contracting leverage, and incremental clinical differentiation. Success in these sectors is measured as frequently as by quarterly shifts in market share or immediate cost-offsets. Federal healthcare does not operate this way. In the federal space, decisions are driven less by competition and more by mission, structure, and accountability. However, each agency providing healthcare has its own set of goals and clinical approaches. Consequently, messaging must be both more than an extension of commercial logic and specific to the mission of the agency approached. This requires a fundamental pivot from commercial market-based persuasion to mission-based alignment because, without this shift, even the most sophisticated commercial strategy will fail to resonate with federal decision-makers.

The Veterans Health Administration (VHA) operates from a longitudinal point of view. The VHA is designed to provide lifelong care to patients who remain within the system for years or even decades. This responsibility dictates a unique clinical focus as VHA generally excels at managing chronic disease, mental health, disability, and rehabilitation. A product’s value is typically assessed through a system-wide lens of impact rather than short-term gains. For example, if a manufacturer’s value proposition is built on a 12-month cost-saving narrative or a rapid clinical turnaround, the narrative fundamentally misses the mark. To the VHA, the most valuable intervention is one that reduces the total longitudinal burden of care and maintains veteran independence over the span of a lifetime. Manufacturers that ignore this timeline often find themselves technically accessible but clinically irrelevant as their commercial logic fails to account for the VHA’s multi-decade clinical horizon.

Conversely, the Defense Health Agency (DHA) operates from a medical readiness point of view. Care is often episodic and optimizes service members for training, deployment, and operational performance. It is also family-based as DHA care is extended to the service member’s family unit. In the DHA, long-term cost narratives often feel disconnected from daily realities and messaging that focuses on long-term longevity or slow-burn outcomes is strategically irrelevant in this environment. Messaging, instead, should focus on both the return of the individual patient’s ability to perform their duties as well as the overall mission of the military branch in which they serve. Ultimately, the DHA rewards interventions that prioritize functional recovery and minimize downtime. In this system, the primary metric of success is the speed at which a member is restored to duty or the family member is served. Commercial logic fails here because it prioritizes general market differentiation over the specific, immediate needs of force readiness and the stability of the military family unit.

Quick Federal Alignment Diagnostic

• The Horizon Test: Is the value proposition anchored in a 12-month commercial cost-offset cycle?

• The Readiness Test: Do the supporting materials rely on general clinical differentiation?

• The Mission Test: Does the narrative reflect the agency’s specific mandate?

  
  

Not meeting these healthcare systems on their terms risks lock out of the clinical conversation and ensures that commercial assumptions become a barrier to true federal access. Manufacturers that focus on becoming mission-aligned partners will find greater adoption and increased utilization. Otherwise, access exists but utilization does not and the manufacturer risks misdiagnosing a positioning problem as an execution error.